Intravenous immunoglobulins in systemic lupus erythematosus: from the bench to the bedside

This article is an update on the clinical and research data available on systemic lupus erythematosus (SLE) and intravenous immunoglobulin (IVIg) therapy that includes some studies performed under the umbrella of the European Working Party on SLE. Various mechanisms of IVIg may play a role, some syn...

Full description

Saved in:
Bibliographic Details
Published in:Lupus 2009-09, Vol.18 (10), p.884-888
Main Authors: Zandman-Goddard, G, Blank, M, Shoenfeld, Y
Format: Article
Language:English
Subjects:
Anti-Inflammatory Agents - therapeutic use
Antibodies
Antibodies, Anti-Idiotypic - therapeutic use
Antigens
Antiphospholipid Syndrome - drug therapy
Autoimmune diseases
Cytokines
Disease
Drug dosages
Humans
Immunoglobulins
Immunoglobulins, Intravenous - adverse effects
Immunoglobulins, Intravenous - pharmacology
Immunoglobulins, Intravenous - therapeutic use
Lupus
Lupus Erythematosus, Systemic - drug therapy
Lymphocytes
Medicine
Peptides
Phosphorylcholine - immunology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This article is an update on the clinical and research data available on systemic lupus erythematosus (SLE) and intravenous immunoglobulin (IVIg) therapy that includes some studies performed under the umbrella of the European Working Party on SLE. Various mechanisms of IVIg may play a role, some synergistically, in the modulation of SLE. Recently it has been suggested that IVIg also suppresses the expansion of autoreactive B lymphocytes through signalling of the FcgRIIB, idiotype-mediated inhibition of B cell receptors and neutralisation of cytokines such as the B cell survival factors (B cell activation factor (BAFF and APRIL). In case reports and in open trials, high-dose IVIg (2 g/kg over a 5-day period) has consistently been shown to be a beneficial and safe adjunct therapeutic agent for over 20 manifestations in patients with SLE. It can be given as a first choice of therapy in some cases, for example, in neurological involvement and in those patients who refuse certain immunosuppressive agents such as cyclophosphamide, or in patients who have concomitant infections. Furthermore, IVIg may have a steroid-sparing effect although this characteristic needs further investigation. Specific IVIg (an anti-idiotype to anti-DNA, phosphorylcholine and antiphospholipids) has been shown to be effective in experimental murine models. Hence, extractable IVIg that is directed to the specific pathogenic immunoglobulins will enable the more specific therapy for patients with lupus.
ISSN:0961-2033
1477-0962
DOI:10.1177/0961203309106921